Continued treatment for patients with cancer near end-of-life escalates costs and may adversely affect the quality of care patients receive. Accordingly, over the last decade, major professional societies have recommended that clinicians decrease the use of systemic anti-cancer therapies at the end-of-life stage. Researchers revealed that despite these recommendations, aggressive cancer care at the end-of-life persists and there has been a substantial transition from the use of chemotherapy to immunotherapy. "Systemic anti-cancer therapy has changed dramatically following the approvals of multiple new targeted therapies," said Kerin Adelson, MD. Researchers used the nationwide Flatiron Health electronic health record (EHR)-derived database to...